Family Heart Foundation/X
Aug 26, 2025, 09:45
FDA Expands Repatha (Evolocumab) Approval: New Options for Adults With Uncontrolled LDL-C and HoFH
Family Heart Foundation posted on X:
”FDA expands approval of Repatha® (evolocumab) for adults at risk of CV events from uncontrolled LDL-C—even without established CVD. Now approved as monotherapy for HoFH. Important update for clinicians managing FH patients.”
Find more information here.
Stay updated with Hemostasis Today.
-
Nov 30, 2025, 13:23Ditte Vestergaard Hansen and Colleagues on Predictors of VTE Post-Stroke
-
Nov 30, 2025, 13:10Divyaswathi Citla Sridhar and Team Report Higher VTE Rates in Obese Users of Certain Estrogen-Progestin Combinations
-
Nov 30, 2025, 12:40Timos Papagatsias: Interested in Social Media in the Hematology Space?
-
Nov 30, 2025, 12:15Raphaël Liévin: In March 2026 SFH Will Host Its Very First Young EHA Research Meeting (YERM)!
-
Nov 30, 2025, 11:51Mohamed Aly Saad Aly on Microcatheters for Superselective Arterial Embolization
-
Nov 29, 2025, 18:55Ahmad Thuaimer: Success Story – Advanced Interventional Care for DVT
-
Nov 29, 2025, 17:37Almahdi Ali Explores Ipsilateral Paradoxical Thromboembolism at 22nd European Angiology Days 2025
-
Nov 29, 2025, 17:23Jack Shuang Hou Shares Major Neurology Updates This Week
-
Nov 29, 2025, 16:52Federica Fogacci on Further Strengthening Collaboration Within the Lp(a)CCELERATE Study